文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-PSMA-11 PET/CT与常规影像评估mCRPC疗效的前瞻性比较

68Ga-PSMA-11 PET/CT Versus Conventional Imaging for Response Evaluation in Metastatic Castration-resistant Prostate Cancer: A Single-center Prospective Study.
PubMed 文献 · Clin Nucl Med · 2025-11-03

结果显示PCWG3总体及ARPI治疗亚组中预后关联最强,RECIP-1.0在非ARPI亚组中C-index最高且读者间一致性最佳。

要点

  • PCWG3标准在总体人群和ARPI治疗患者中预后价值最佳。
  • RECIP-1.0在非ARPI患者中rPFS对OS的替代性C-index最高(C=0.76)。
  • RECIP-1.0的读者间一致性最高(κ=0.84)。

核心结论

  • PCWG3仍是总体和ARPI治疗患者最有效的疗效评估标准,RECIP-1.0对非ARPI患者预后价值更好。

研究设计与样本

  • 基线及每12周治疗后行68Ga-PSMA-11 PET/CT和常规影像(CECT和骨显像)。

主要发现

  • 12周无进展率:PCWG3为23.5%,aPERCIST为8.8%,PPP为17.6%,RECIP-1.0为23.5%。
  • RECIP-1.0读者间一致性最高(κ=0.84)。
  • 中位OS为16.5个月,仅PCWG3无进展与显著更好的OS相关(P=0.02)。
  • rPFS对OS替代分析中,PCWG3-rPFS的C-index最高(C=0.72),RECIP-rPFS次之(C=0.71)。

关键数值与推荐

  • 非ARPI亚组中RECIP-rPFS的C-index最高(C=0.76),ARPI亚组中PCWG3-rPFS最高(C=0.75)。

临床怎么用

  • 总体及ARPI治疗mCRPC患者疗效评估可优先采用PCWG3标准。
  • 非ARPI治疗患者可考虑RECIP-1.0作为补充评估工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with metastatic castration-resistant prostate cancer (mCRPC) often undergo multiple treatments, making accurate response assessment vital. The conventional imaging-based PCWG3 criteria, incorporating the RECIST-1.1, have been the gold standard so far. Although 68Ga-PSMA-11-PET/CT has shown an incremental role in staging of prostate cancer, its utility in response evaluation lacks prospective validation. Here, we prospectively evaluate different 68Ga-PSMA-11-PET/CT-based response evaluation criteria, including RECIP-1.0, PPP, and aPERCIST, and compare these with the PCWG3 criteria. METHODS: mCRPC patients, initiating treatment with taxanes, androgen-receptor pathway inhibitors (ARPIs), or 177Lu-PSMA-617, underwent 68Ga-PSMA-11-PET/CT and conventional imaging (CECT and bone scintigraphy) at baseline, and every 12 weeks after treatment. RESULTS: Thirty-four mCRPC patients were included (median age: 68.5 y, median PSA: 61.9 ng/mL). Nonprogression rates at 12 weeks according to PCWG3, aPERCIST, PPP, and RECIP-1.0 were 23.5%, 8.8%, 17.6%, and 23.5%, respectively. The highest inter-reader agreement was observed with RECIP-1.0 (κ=0.84). The median OS was 16.5 months with nonprogression according to PCWG3 being associated with significantly better OS (P=0.02), and no significant associations were observed with the rest of the criteria. In surrogacy analysis of rPFS for OS in the overall cohort, the highest C-index was observed for PCWG3-rPFS (C=0.72), followed by RECIP-rPFS (C=0.71). In subgroup analyses, RECIP-rPFS had the highest C-index for non-ARPI patients (C=0.76), and PCWG3-rPFS for the ARPI patients (C=0.75). CONCLUSIONS: PCWG3 remains the most effective response criterion overall and for ARPI-treated patients, while RECIP-1.0 showed better prognostic value for non-ARPI patients. Larger studies are needed to validate these findings.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Preet K, Sood A, Satapathy S, et al. 68Ga-PSMA-11 PET/CT Versus Conventional Imaging for Response Evaluation in Metastatic Castration-resistant Prostate Cancer: A Single-center Prospective Study. Clin Nucl Med. 2025. PMID: 41499309. doi:10.1097/RLU.0000000000006147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。